my account
log out
|
|
my account
log out
|
transferrin-PE immunotoxin |
| Create: 03/30/2017 |
| Expired Date: | 03/13/2020 |
| Category: | Drugs&Pharmaceutical [Health&Medical&Pharmaceutical] |
| Message: | This immunotoxin was achieved by conjugating/fusing the transferrin to Pseudomonas exotoxin. It was expressed in CHO and purified with affinity chromatography. The immunotoxin selectively binds to TFRC expressing cells and enters cells by receptor-mediated endocytosis, then PE cleaved fragments the size of Mr 37000 and 27000, the large fragment and finally into the Golgi and elongation factor 2 (EM) combining it glycosylation inactivation, inhibition of protein synthesis, leading to apoptosis. It was designed for treatment of T cell leukemias or lymphomas, graft-versus-host diseases, and autoimmune diseases. |
| City: | Shirley[US]
 |
| Location: |
|
| Feb 01 2023 | VBS++ (with Ca and Mg) Buffer | 269 | |
| Feb 01 2023 | GVBE Buffer | 277 | |
| Feb 01 2023 | GVB++ (with Ca and Mg) Buffer | 277 | |
| Feb 01 2023 | Hemolysin (Rabbit Anti-Sheep Cell Hemolysin) | 272 | |
| Aug 30 2019 |  | Anti-HSV-2 gH Antibody | 463 |
| Aug 30 2019 | | Anti-L. major LPG Antibody | 545 |
| Aug 30 2019 | | Anti-DENV-1 Antibody | 453 |
| Aug 30 2019 | | Anti-BPV-1 L1 Antibody | 467 |
| Aug 30 2019 | | Anti-H3N2 HA Antibody | 455 |
| Aug 30 2019 | | Anti-EIAV env Antibody | 476 |
| Copyright © toextrade Inc. All rights reserved. Contact us |